* Avid Bioservices Inc reported a quarterly adjusted loss of 9 cents per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of five analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -7 cents to -3 cents per share.
* Revenue fell 11.1% to $33.82 million from a year ago; analysts expected $33.45 million.
* Avid Bioservices Inc's reported EPS for the quarter was a loss of 9 cents.
* The company reported a quarterly loss of $6.01 million.
* Avid Bioservices Inc shares had fallen by 0.3% this quarter and gained 2.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Avid Bioservices Inc is $13.00 This summary was machine generated from LSEG data April 24 at 09:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 31 2024 -0.05 -0.09 Missed
Oct. 31 2023 -0.06 -0.15 Missed
Jul. 31 2023 -0.03 -0.03 Met
Apr. 30 2023 0.00 0.00 Met
Comments